$0.42

($0.0300)

-6.6667

PetVivo Holdings Provides Shareholder Update

MINNEAPOLIS, MN / ACCESSWIRE / October 17, 2017 / PetVivo Holdings, Inc. (OTC PINK: PETV) (www.petvivo.com) an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets and people is pleased to provide an update to our shareholders.

Information and skilled execution has always led the way to success. It is important to us, the management team of your company, be committed to informing all shareholders of the progress that has been made and is currently underway. Several major steps forward have been taken in the last few months, and there is potentially more to come in the next few.

First, I will address the management changes and additions. I accepted the position of CEO and Board Member in June. At the end of August, Cynthia Jenkins joined the company as CFO. The month of September saw the addition of David Deming and Peter Vezmar to the Board of Directors. October solidified the addition of Robin Young and Michael Haider to the Advisory Board. All of the business biographies of these individuals are posted on our website (www.petvivo.com).

Second, as a reporting company, PetVivo has continued the effort to catch up on delinquent filings. It is projected that the final filing to bring the company current with the Securities and Exchange Commission will be submitted in early November. Once current our financial results will be available at most financial web portals that provide financial data.

PetVivo has a new home that is in final construction in Edina, Minnesota. Corporate offices, Research and Commercial production facilities will be ready for full operation on December 1st. The first commercial runs of "Kush" will be supporting the sales and marketing roll out scheduled to commence at the same time. We are currently assembling the sales and distribution team that will introduce our first product.

Financial support for these activities comes from the completion and oversold round of $525,000 of financing, which ended only last week. The funding is expected to complete the construction and fund the early stages of market and sales.

The stock (PETV) has experienced considerable appreciation over the last six months as confidence by investors has grown with the company achieving specific benchmarks. The practice of goal setting, short term and long term has become the norm among the management of your company. We continue to push forward each and every day to make our products a primary component in the canine, equine and eventually human solutions for the future.

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTC PINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo's strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company's product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company's products, production processes and biomaterials. PetVivo's lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.

The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.

Forward-Looking commercial Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.